Rogers

Yahoo Finance • 4 months ago

Roche showcases solutions for laboratories of the future at the Association for Diagnostics & Laboratory Medicine 2024 Clinical Lab Expo

Roche will unveil the next generation of core lab and molecular systems, including a total solution for clinical mass spectrometry. Attendees can experience firsthand how fully integrated systems and data solutions can streamline lab opera... Full story

Yahoo Finance • 9 months ago

Rogers Corporation (NYSE:ROG) Q4 2023 Earnings Call Transcript

Rogers Corporation (NYSE:ROG) Q4 2023 Earnings Call Transcript February 21, 2024 Rogers Corporation misses on earnings expectations. Reported EPS is $0.6 EPS, expectations were $1. Rogers Corporation isn’t one of the 30 most popular stock... Full story

Yahoo Finance • last year

Rogers to Participate in UBS Global Technology Conference

CHANDLER, Ariz., November 21, 2023--(BUSINESS WIRE)--Rogers Corporation (NYSE:ROG) announced today that Colin Gouveia, President and Chief Executive Officer, and Ram Mayampurath, Senior Vice President and Chief Financial Officer, will part... Full story

Yahoo Finance • 2 years ago

Rogers Corporation Reports Fourth Quarter and Full Year 2022 Results

Implemented Additional Actions to Streamline Operations and Increase Profitability CHANDLER, Ariz., February 28, 2023--(BUSINESS WIRE)--Rogers Corporation (NYSE:ROG) today announced financial results for the full year and fourth quarter o... Full story

Yahoo Finance • 2 years ago

Rogers reaches agreement with Starboard Value; to add two directors to board

MARKET PULSE Rogers Corp. (ROG) said Monday it has reached an agreement with activist shareholder Starboard Value LP and will add two independent directors to its board. Starboard owns about 6.5% of Rogers’ stock. Continue reading... Full story

Yahoo Finance • 2 years ago

DuPont Scraps Deal to Buy Rogers After Failing to Win Regulatory Clearance

DuPont de Nemours Inc. has abandoned its $5.2 billion deal to buy electronics-materials specialist Rogers Corp. after the companies couldn’t win approval from all regulators. DuPont is paying Rogers a $162.5 million breakup fee to terminat... Full story

Yahoo Finance • 3 years ago

U.S. FDA grants priority review to Roche’s Actemra/RoActemra for the treatment of COVID-19 in hospitalised adults

F. Hoffmann-La Roche Ltd If approved, Actemra/RoActemra would be the first U.S. FDA-approved immunomodulator for the treatment of COVID-19 in hospitalised patients Since the beginning of the pandemic, more than one million people hospital... Full story

Yahoo Finance • 3 years ago

U.S. FDA Grants Priority Review to Genentech’s Actemra for the Treatment of COVID-19 in Hospitalized Adults

– If approved, Actemra would be the first U.S. FDA-approved immunomodulator for the treatment of COVID-19 in hospitalized patients – – Since the beginning of the pandemic, more than one million people hospitalized with COVID-19 have been... Full story

Yahoo Finance • 3 years ago

New Data for Genentech’s Ocrevus (ocrelizumab) Show Benefit in Disability Progression and Cognitive Decline in Both Secondary Progressive and Primary Progressive Multiple Sclerosis

– 75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression (NEP) in a one-year interim analysis of CONSONANCE study – – 70% of patients with SPMS and PPMS d... Full story

Yahoo Finance • 3 years ago

New data for Roche’s OCREVUS (ocrelizumab) show benefit in disability progression and cognitive decline in both secondary progressive and primary progressive multiple sclerosis

F. Hoffmann-La Roche Ltd 75% of patients with secondary progressive multiple sclerosis (SPMS) and primary progressive MS (PPMS) achieved no evidence of progression (NEP) in a one-year interim analysis of CONSONANCE study 70% of patients... Full story

Yahoo Finance • 3 years ago

Here's Why We're Not Too Worried About Red Sky Energy's (ASX:ROG) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after listing, if you had bought and held the sh... Full story

Yahoo Finance • 3 years ago

Genentech to Present Data Across Broad and Impactful Neuroscience Portfolio at 2022 AAN Annual Meeting

– First data showing Ocrevus (ocrelizumab) treatment effect on disability progression in non-active secondary progressive multiple sclerosis and further data in primary progressive multiple sclerosis will be presented – – Evrysdi (risdipl... Full story

Yahoo Finance • 3 years ago

Roche to present data across broad and impactful neuroscience portfolio at 2022 AAN Annual Meeting

F. Hoffmann-La Roche Ltd First data showing OCREVUS treatment effect on disability progression in non-active secondary progressive multiple sclerosis and further data in primary progressive MS will be presented Evrysdi data continue to de... Full story